Navigation Links
Accuray Elevated to NASDAQ Global Select Market
Date:1/3/2011

SUNNYVALE, Calif., Jan. 3, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it has been named to the NASDAQ Global Select Market, the premier listing tier for NASDAQ companies. The NASDAQ Global Select Market is designated for public companies that meet the highest listing standards in the world, with measures including market value, liquidity and earnings.

"We are honored to be added to the NASDAQ Global Select Market, joining some of the most respected companies in the world who also uphold NASDAQ's rigorous qualification standards," said Euan Thomson, Ph.D., president and CEO of Accuray. "In the last year, we have celebrated several milestones including the FDA clearance of the CyberKnife System's Lung Optimized Treatment, the launch of the CyberKnife VSI System and our 200th worldwide install. Inclusion in this listing further emphasizes our overall growth as a company, as well as our solid financial performance and long-term growth potential."

Accuray was previously listed on the NASDAQ Global Market. Accuray's shares will be transferred to the Global Select Market at the opening of business today, January 3, 2011, and will continue to be traded under the ticker ARAY.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to company growth and performance, and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: average treatment times, range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on November 8, 2010 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Incorporateds CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference
2. Accuray Establishes Medical Affairs Function
3. Accuray Receives FDA Clearance for the CyberKnife® Systems Lung Optimized Treatment
4. Accuray Announces Results for First Quarter of Fiscal 2011
5. Accuray Announces Expanded Service Program
6. Accurays CyberKnife VSI System Featured at 2010 American Society for Radiation Oncology (ASTRO) Annual Meeting
7. Accuray Hires General Manager for the Asia Pacific Region
8. Accuray Incorporated to Speak at Oppenheimers 21st Annual Healthcare Conference
9. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2011
10. Accuray Ranked Number 113 Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
11. Accuray Incorporated to Host Analyst Meeting at ASTRO 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):